Role of brain kallikrein-kinin system in regulation of adrenocorticotropin release

P. Madeddu, V. Anania, S. Alagna, C. Troffa, P. P. Parpaglia, G. Tonolo, M. P. Demontis, M. V. Varoni, C. Fattaccio, N. Glorioso

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We evaluated whether the brain kallikrein-kinin system plays a role in the regulation of adrenocorticotropin (ACTH) release in rats. Intracerebroventricular (icv) injection of bradykinin (0.24 nmol) increased plasma immunoreactive ACTH (irACTH) levels (from 93 ± 4 to 200 ± 12 pg/ml, P <0.01). This effect was prevented by icv kinin antagonist at 15.4 nmol/h (from 98 ± 5 to 108 ± 6 pg/ml; not significant). The antagonist did not alter the increase in plasma irACTH levels induced by icv corticotropin- releasing factor (CRF), arginine vasopressin, or prostaglandin E2. Melittin (7 nmol/h icv) increased plasma irACTH from 95 ± 4 to 268 ± 7 pg/ml (P <0.01). This effect was prevented by icv kinin antagonist (15.4 nmol/h), kallikrein antibodies (13 pmol/h), or indomethacin (0.28 mmol/h). ACTH response to melittin was not altered by antagonists of CRF or vasopressin. Intra-arterial injection of insulin (0.3 IU/kg body wt) reduced plasma glucose levels to a similar extent in rats given icv kinin antagonist or vehicle; the ACTH response to insulin-induced hypoglycemia was slightly less in rats given kinin antagonist than in those given vehicle (55 ± 5 vs. 86 ± 4 pg/ml, P <0.05). The brain kallikrein-kinin system may play a role in the regulation of ACTH secretion in stimulated conditions.

Original languageEnglish
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume262
Issue number3 25-3
Publication statusPublished - 1992

Fingerprint

Kallikrein-Kinin System
Kinins
Kallikreins
Adrenocorticotropic Hormone
Brain
Melitten
Plasmas
Rats
Corticotropin-Releasing Hormone
Insulin
Intra-Arterial Injections
Arginine Vasopressin
Bradykinin
Vasopressins
Hypoglycemia
Dinoprostone
Indomethacin
Glucose
Injections
Antibodies

Keywords

  • melittin
  • pituitary

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology

Cite this

Madeddu, P., Anania, V., Alagna, S., Troffa, C., Parpaglia, P. P., Tonolo, G., ... Glorioso, N. (1992). Role of brain kallikrein-kinin system in regulation of adrenocorticotropin release. American Journal of Physiology - Endocrinology and Metabolism, 262(3 25-3).

Role of brain kallikrein-kinin system in regulation of adrenocorticotropin release. / Madeddu, P.; Anania, V.; Alagna, S.; Troffa, C.; Parpaglia, P. P.; Tonolo, G.; Demontis, M. P.; Varoni, M. V.; Fattaccio, C.; Glorioso, N.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 262, No. 3 25-3, 1992.

Research output: Contribution to journalArticle

Madeddu, P, Anania, V, Alagna, S, Troffa, C, Parpaglia, PP, Tonolo, G, Demontis, MP, Varoni, MV, Fattaccio, C & Glorioso, N 1992, 'Role of brain kallikrein-kinin system in regulation of adrenocorticotropin release', American Journal of Physiology - Endocrinology and Metabolism, vol. 262, no. 3 25-3.
Madeddu, P. ; Anania, V. ; Alagna, S. ; Troffa, C. ; Parpaglia, P. P. ; Tonolo, G. ; Demontis, M. P. ; Varoni, M. V. ; Fattaccio, C. ; Glorioso, N. / Role of brain kallikrein-kinin system in regulation of adrenocorticotropin release. In: American Journal of Physiology - Endocrinology and Metabolism. 1992 ; Vol. 262, No. 3 25-3.
@article{6810c77e0fc44f36be77203011f872f9,
title = "Role of brain kallikrein-kinin system in regulation of adrenocorticotropin release",
abstract = "We evaluated whether the brain kallikrein-kinin system plays a role in the regulation of adrenocorticotropin (ACTH) release in rats. Intracerebroventricular (icv) injection of bradykinin (0.24 nmol) increased plasma immunoreactive ACTH (irACTH) levels (from 93 ± 4 to 200 ± 12 pg/ml, P <0.01). This effect was prevented by icv kinin antagonist at 15.4 nmol/h (from 98 ± 5 to 108 ± 6 pg/ml; not significant). The antagonist did not alter the increase in plasma irACTH levels induced by icv corticotropin- releasing factor (CRF), arginine vasopressin, or prostaglandin E2. Melittin (7 nmol/h icv) increased plasma irACTH from 95 ± 4 to 268 ± 7 pg/ml (P <0.01). This effect was prevented by icv kinin antagonist (15.4 nmol/h), kallikrein antibodies (13 pmol/h), or indomethacin (0.28 mmol/h). ACTH response to melittin was not altered by antagonists of CRF or vasopressin. Intra-arterial injection of insulin (0.3 IU/kg body wt) reduced plasma glucose levels to a similar extent in rats given icv kinin antagonist or vehicle; the ACTH response to insulin-induced hypoglycemia was slightly less in rats given kinin antagonist than in those given vehicle (55 ± 5 vs. 86 ± 4 pg/ml, P <0.05). The brain kallikrein-kinin system may play a role in the regulation of ACTH secretion in stimulated conditions.",
keywords = "melittin, pituitary",
author = "P. Madeddu and V. Anania and S. Alagna and C. Troffa and Parpaglia, {P. P.} and G. Tonolo and Demontis, {M. P.} and Varoni, {M. V.} and C. Fattaccio and N. Glorioso",
year = "1992",
language = "English",
volume = "262",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "3 25-3",

}

TY - JOUR

T1 - Role of brain kallikrein-kinin system in regulation of adrenocorticotropin release

AU - Madeddu, P.

AU - Anania, V.

AU - Alagna, S.

AU - Troffa, C.

AU - Parpaglia, P. P.

AU - Tonolo, G.

AU - Demontis, M. P.

AU - Varoni, M. V.

AU - Fattaccio, C.

AU - Glorioso, N.

PY - 1992

Y1 - 1992

N2 - We evaluated whether the brain kallikrein-kinin system plays a role in the regulation of adrenocorticotropin (ACTH) release in rats. Intracerebroventricular (icv) injection of bradykinin (0.24 nmol) increased plasma immunoreactive ACTH (irACTH) levels (from 93 ± 4 to 200 ± 12 pg/ml, P <0.01). This effect was prevented by icv kinin antagonist at 15.4 nmol/h (from 98 ± 5 to 108 ± 6 pg/ml; not significant). The antagonist did not alter the increase in plasma irACTH levels induced by icv corticotropin- releasing factor (CRF), arginine vasopressin, or prostaglandin E2. Melittin (7 nmol/h icv) increased plasma irACTH from 95 ± 4 to 268 ± 7 pg/ml (P <0.01). This effect was prevented by icv kinin antagonist (15.4 nmol/h), kallikrein antibodies (13 pmol/h), or indomethacin (0.28 mmol/h). ACTH response to melittin was not altered by antagonists of CRF or vasopressin. Intra-arterial injection of insulin (0.3 IU/kg body wt) reduced plasma glucose levels to a similar extent in rats given icv kinin antagonist or vehicle; the ACTH response to insulin-induced hypoglycemia was slightly less in rats given kinin antagonist than in those given vehicle (55 ± 5 vs. 86 ± 4 pg/ml, P <0.05). The brain kallikrein-kinin system may play a role in the regulation of ACTH secretion in stimulated conditions.

AB - We evaluated whether the brain kallikrein-kinin system plays a role in the regulation of adrenocorticotropin (ACTH) release in rats. Intracerebroventricular (icv) injection of bradykinin (0.24 nmol) increased plasma immunoreactive ACTH (irACTH) levels (from 93 ± 4 to 200 ± 12 pg/ml, P <0.01). This effect was prevented by icv kinin antagonist at 15.4 nmol/h (from 98 ± 5 to 108 ± 6 pg/ml; not significant). The antagonist did not alter the increase in plasma irACTH levels induced by icv corticotropin- releasing factor (CRF), arginine vasopressin, or prostaglandin E2. Melittin (7 nmol/h icv) increased plasma irACTH from 95 ± 4 to 268 ± 7 pg/ml (P <0.01). This effect was prevented by icv kinin antagonist (15.4 nmol/h), kallikrein antibodies (13 pmol/h), or indomethacin (0.28 mmol/h). ACTH response to melittin was not altered by antagonists of CRF or vasopressin. Intra-arterial injection of insulin (0.3 IU/kg body wt) reduced plasma glucose levels to a similar extent in rats given icv kinin antagonist or vehicle; the ACTH response to insulin-induced hypoglycemia was slightly less in rats given kinin antagonist than in those given vehicle (55 ± 5 vs. 86 ± 4 pg/ml, P <0.05). The brain kallikrein-kinin system may play a role in the regulation of ACTH secretion in stimulated conditions.

KW - melittin

KW - pituitary

UR - http://www.scopus.com/inward/record.url?scp=0026608712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026608712&partnerID=8YFLogxK

M3 - Article

C2 - 1312788

AN - SCOPUS:0026608712

VL - 262

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 3 25-3

ER -